Rheumatoid arthritis: a case for personalized health care?

scientific article published on September 2014

Rheumatoid arthritis: a case for personalized health care? is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1002/ACR.22289
P698PubMed publication ID24470057

P50authorAdam PlattQ70920128
Morten Asser KarsdalQ88536436
Anne C Bay-JensenQ91708937
P2093author name stringClaus Christiansen
Kim Henriksen
Harry K Genant
Chris Chamberlain
P2860cites workLong-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysisQ24655666
ACR/EULAR 2010 rheumatoid arthritis classification criteriaQ26864171
Denosumab for prevention of fractures in postmenopausal women with osteoporosisQ28254528
Genome-wide association analysis implicates the involvement of eight loci with response to tocilizumab for the treatment of rheumatoid arthritisQ28943301
Procollagen type I N-terminal propeptide (PINP) is a marker for fibrogenesis in bile duct ligation-induced fibrosis in ratsQ33813357
Matrix as a modulator of hepatic fibrogenesisQ34391368
Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysisQ34395462
Treating rheumatoid arthritis to target: recommendations of an international task forceQ34462557
Predicting future response to certolizumab pegol in rheumatoid arthritis patients: features at 12 weeks associated with low disease activity at 1 yearQ35899269
The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patientsQ36245889
Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failureQ36672445
An evaluation of molecular and clinical remission in rheumatoid arthritis by assessing radiographic progressionQ36778521
Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: exploratory analyses from the TEMPO trialQ36974786
IL-6 pathway-driven investigation of response to IL-6 receptor inhibition in rheumatoid arthritisQ37121710
Identification of progressors in osteoarthritis by combining biochemical and MRI-based markersQ37350908
Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug developmentQ37462448
Serological identification of fast progressors of structural damage with rheumatoid arthritis.Q37689708
Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugsQ37707612
Novel combinations of Post-Translational Modification (PTM) neo-epitopes provide tissue-specific biochemical markers--are they the cause or the consequence of the disease?Q37728368
When is switching warranted among biologic therapies in rheumatoid arthritis?Q38027571
Forget personalised medicine and focus on abating disease activityQ38058492
Impact of a multi-biomarker disease activity test on rheumatoid arthritis treatment decisions and therapy use.Q38061932
Immunogenicity and autoimmunity during anti-TNF therapy.Q38064661
Evolution of treatment for rheumatoid arthritisQ38065767
The potential use of expression profiling: implications for predicting treatment response in rheumatoid arthritisQ38088942
Osteoarthritis--a case for personalized health care?Q38161654
Pharmacological induction of interferon type I activity following treatment with rituximab determines clinical response in rheumatoid arthritisQ38502821
The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone increases bone resorption in women with type 2 diabetes: a randomized, controlled trialQ43114233
Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetesQ43252247
Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective studyQ43300360
Pretreatment synovial transcriptional profile is associated with early and late clinical response in rheumatoid arthritis patients treated with rituximabQ43701379
The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation.Q44431651
Identification and characterisation of osteoarthritis patients with inflammation derived tissue turnover.Q44609355
Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosisQ44616456
Characterization of a multiplex, 12-biomarker test for rheumatoid arthritisQ45347170
Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysisQ46068649
Serum concentrations of formation (PINP) and resorption (Ctx) bone turnover markers in rheumatoid arthritisQ46121066
American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritisQ47643186
Tocilizumab and missed personalized medicine opportunities for patients with rheumatoid arthritis?Q47911708
Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trialQ49218023
Chipping away at the lung cancer genome.Q54525027
A novel assay for extracellular matrix remodeling associated with liver fibrosis: An enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagenQ57279145
P433issue9
P921main subjectrheumatoid arthritisQ187255
P304page(s)1273-1280
P577publication date2014-09-01
P1433published inArthritis Care and ResearchQ15754720
P1476titleRheumatoid arthritis: a case for personalized health care?
P478volume66

Reverse relations

cites work (P2860)
Q52806365Age-related collagen turnover of the interstitial matrix and basement membrane: Implications of age- and sex-dependent remodeling of the extracellular matrix.
Q90102556Defining response to TNF-inhibitors in rheumatoid arthritis: the negative impact of anti-TNF cycling and the need for a personalized medicine approach to identify primary non-responders
Q36481786Early changes in blood-based joint tissue destruction biomarkers are predictive of response to tocilizumab in the LITHE study
Q64091799Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept
Q98564934Identification of heterogenous treatment response trajectories to anti-IL6 receptor treatment in rheumatoid arthritis
Q92146862Identification of pathological RA endotypes using blood-based biomarkers reflecting tissue metabolism. A retrospective and explorative analysis of two phase III RA studies
Q28551216Independent Candidate Serum Protein Biomarkers of Response to Adalimumab and to Infliximab in Rheumatoid Arthritis: An Exploratory Study
Q37694959NLRP3 and CARD8 Polymorphisms Influence Higher Disease Activity in Rheumatoid Arthritis
Q35971518Neo-Epitopes--Fragments of Cartilage and Connective Tissue Degradation in Early Rheumatoid Arthritis and Unclassified Arthritis
Q38675211Protein degradation fragments as diagnostic and prognostic biomarkers of connective tissue diseases: understanding the extracellular matrix message and implication for current and future serological biomarkers
Q91973492The Emerging Jamboree of Transformative Therapies for Autoimmune Diseases
Q64229636Tissue metabolite of type I collagen, C1M, and CRP predicts structural progression of rheumatoid arthritis
Q53820042Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis.

Search more.